Receptos announced that the U.S. Patent and Trademark Office has issued U.S. Patent Nos. 8,466,183 and 8,481,573 which cover compounds including the company's proprietary selective sphingosine-1-phosphate 1 receptor modulator, RPC1063. These composition of matter patents will have an initial patent term extending to May 2029. In addition to the issued U.S. patents, multiple additional patent applications are undergoing prosecution that are anticipated to provide a strong intellectual property estate around RPC1063.
- Company Legal & Law Matters